|
|
| | | What you need to know about the coronavirus today |
| |
Texas, California governors take heat over school reopenings Texas Governor Greg Abbott sought to reassure parents he is doing all he can to keep students safe as most schools in the state prepare to reopen next week. But a top adviser to Democratic presidential contender Joe Biden’s campaign in Texas blasted Abbott, a Republican, for what he called a lack of planning and funding for safely reopening schools, with the statewide coronavirus positivity rate hitting a record 24.5% this week. “What we learned from the reopening of the Texas economy is that if you don’t do it right, people are going to die,” said Mike Collier, senior adviser to the Biden campaign in Texas.
COVID-19 ensnares elderly ICE detainee from Canada After dozens of transferees to a Virginia ICE detention center tested positive for COVID-19, the virus engulfed nearly everyone inside. That included one 72-year-old detainee.
Trump holds up coronavirus aid to block funding for mail-in voting Trump said he was blocking Democrats’ effort to include funds for the U.S. Postal Service and election infrastructure in a new coronavirus relief bill, a bid to block more Americans from voting by mail during the pandemic. Congressional Democrats accused Trump of trying to damage the struggling Postal Service to improve his chances of being re-elected as opinion polls show him trailing presumptive Joe Biden.
China Sinopharm's potential COVID-19 vaccine triggers antibodies in clinical trials A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group, Sinopharm, appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said. The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Britain lines up more potential COVID-19 vaccine supplies with J&J and Novavax deals Britain will buy potential COVID-19 vaccines from drugmakers Johnson & Johnson and Novavax, the companies said, boosting the number of deals it has with drugmakers as the global vaccine race rages on. Britain and the United States are in the lead with six vaccine deals with drugmakers each, as companies and governments worldwide work overtime to find a vaccine against the global pandemic. The latest agreements bring Britain’s total number of doses secured to 362 million for a population of 66 million. | |
| |
| |
Reuters reporters and editors around the world are investigating the response to the coronavirus pandemic.
We need your help to tell these stories. Our news organization wants to capture the full scope of what’s happening and how we got here by drawing on a wide variety of sources. Here’s a look at our coverage.
Are you a government employee or contractor involved in coronavirus testing or the wider public health response? Are you a doctor, nurse or health worker caring for patients? Have you worked on similar outbreaks in the past? Has the disease known as COVID-19 personally affected you or your family? Are you aware of new problems that are about to emerge, such as critical supply shortages?
We need your tips, firsthand accounts, relevant documents or expert knowledge. Please contact us at coronavirus@reuters.com.
We prefer tips from named sources, but if you’d rather remain anonymous, you can submit a confidential news tip. Here’s how. | |
|
| |
|
|
|
|
| | Top Stories on Reuters TV |
|
| |
|
|
|